Stock Update (NASDAQ:RPRX): Repros Therapeutics Inc Announces FDA Advisory Committee Meeting To Discuss Secondary Hypogonadism
Repros Therapeutics Inc (NASDAQ:RPRX) noted that it will participate as a sponsor in a forthcoming public advisory committee meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee recently announced by the Food and Drug Administration (FDA). The general function of the committee is to provide advice and recommendations to the FDA on the FDA’sregulatory issues. The meeting, to be held on December 6, 2016, from 8 a.m. to 5 p.m., will be open to the public.
The announced agenda follows:
“Agenda: The committee will discuss appropriate clinical trial design features, including acceptable endpoints for demonstrating clinical benefit, for drugs intended to treat secondary hypogonadism while preserving or improving testicular function, including spermatogenesis.” (Original Source)
Shares of Repros are currently trading at $2.20, up $0.04 or 1.85%. RPRX has a 1-year high of $8.35 and a 1-year low of $0.80. The stock’s 50-day moving average is $2.08 and its 200-day moving average is $1.84.
Repros Therapeutics, Inc. is a development stage company. The company operates as a biopharmaceutical company, which focuses on the development of new drugs to treat hormonal and reproductive system disorders. Its current product pipeline consists of Enclomiphene and Proellex.